Sirnaomics is a biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference technology.
Sirnaomics is a clinical-stage biopharmaceutical company developing therapeutics for critical human diseases by using RNA interference (RNAi) technology.The RNAi technology is used to discover and develop novel therapeutics with a focus on oncology, anti-fibrotic therapeutics, and viral infection. Its proprietary Polypeptide Nano-Particle (PNP) technology is used for small interfering RNA (siRNA) drug delivery. This technology allows accessing the tumor micro-environment (TME), as well as various cell types in the liver.Sirnaomics was founded by Patrick Y. Lu and David M. Evans in 2007 and is based in Gaithersburg, Maryland.
| Announced Date | Round | Money Raised | Number of Investors | Lead Investors | Post Valuation | |
|---|---|---|---|---|---|---|
| Jul 1, 2021 | Series E | $105M | 2 |
Rotating Boulder Fund
|
— | Detail |
| Oct 23, 2020 | Series D | $105M | 7 |
River Head Capital
Rotating Boulder Fund
Walvax Biotechnology
|
— | Detail |
| Apr 29, 2019 | Series C | $22M | 4 |
|
— | Detail |
| Jun 6, 2018 | Series C | $25M | 4 |
Guangzhou Yuexiu Industrial Investment Fund
|
— | Detail |
| Apr 28, 2016 | Series B | $10M | 1 |
|
— | Detail |
| Investor Name | Lead Investor | Funding Round |
|---|---|---|
Rotating Boulder Fund
|
Yes | Series E |
River Head Capital
|
Yes | Series D |
Walvax Biotechnology
|
Yes | Series D |
|
|
Yes | Series C |
Guangzhou Yuexiu Industrial Investment Fund
|
Yes | Series C |
|
|
Yes | Series B |
Founder H Fund
|
— | Series E |
Alpha Win Capital
|
— | Series D |
|
|
— | Series D |
Longmen Capital
|
— | Series D |